Introduction {#s1}
============

Renal cell carcinoma (RCC) is an insidious neoplasm, accounting for approximately 2% of global cancer diagnoses and deaths, and projected to increase in burden worldwide \[[@R01]\]. Cancers of the kidney and renal pelvis have rapidly become more common in the developed world over the past decades, more than doubling in incidence in the United States (US) since 1975 \[[@R02]\].

Most RCCs occur in the cortex of the kidney, which is composed of the glomerulus, tubular apparatus and collecting duct. Cancers of the renal pelvises resemble urothelial (bladder) cancer in histology and behavior \[[@R03]\].

Most RCC cases in the developed world are found incidentally on imaging, typically with a magnetic resonance imaging (MRI), computed tomography (CT) scan, or ultrasound. Only 10% of patients present with the "classic triad" of symptoms: hematuria, flank pain and palpable masses. Other common symptoms include fever, weight loss and leukocytosis. Approximately 20% of patients also suffer from a variety of paraneoplastic syndromes, including hypercalcemia due to parathyroid-related hormone peptide, polycythemia due to erythropoietin, Cushing's syndrome due to adrenocorticotropic hormone (ACTH) and hypertension due to renin over-production. Rarely, RCC is suspected following the diagnosis of a left-sided varicocele due to tumor involvement and obstruction of the left renal vein \[[@R04]\].

Depending on patient characteristics and extent of the disease, the neoplasm is either surgically resected and ablated or percutaneously biopsied and immunohistochemically (IHC) stained to determine systemic therapy. The IHC stain for the immunosuppressive marker programmed death ligand-1 (PDL1) has become especially predictive as PD-1 inhibitors like pembrolizumab and nivolumab have become the first-line standard of care in PDL1-positive metastatic disease \[[@R05]\]. PDL1-positive disease accounts for approximately 8.2% of cases and is associated with more advanced disease and lower survival \[[@R06]\]. Even PDL1-negative disease is highly resistant to chemotherapy and radiation therapy, other immunotherapies such as aldesleukin (IL-2) and targeted therapies (such as sunitinib, a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor) are typically employed in the treatment of the metastatic disease.

As more nations adopt the Western lifestyle, the global burden of RCC is projected to continue to rapidly increase. Incidental findings remain the primary form of RCC diagnosis, and despite new treatment options, late-stage diagnoses have abysmally low survival rates. A better understanding of RCC epidemiology and risk factors may help curb growing disease burden through prevention as well as facilitate earlier diagnosis and more targeted treatment options, thereby improving survival for a disease that claims 175,000 lives each year.

Epidemiology {#s2}
============

Incidence {#s2a}
---------

According to 2018 GLOBOCAN data, an estimated 403,000 people a year are diagnosed with neoplasms of the kidney, constituting 2.2% of all cancer diagnoses \[[@R07]\]. Of these, approximately 254,500 cases are diagnosed in males and 148,800 in females, reflecting a relative risk (RR) of about 1.7 for men compared to women. The cumulative global risk of developing the disease is 0.69% among men and 0.35% among women, which results in an age-standardized rate (ASR) of 6.0 and 3.1 among men and women, respectively (with a global average of 4.4). North America has the greatest incidence (ASR = 10.9/100,000) with Western Europe (9.7) and Australia/New Zealand (9.6) not far behind ([Fig. 1](#F1){ref-type="fig"} \[[@R07]\]). Belarus is the nation with the highest incidence in the world (16.8/100,000), while many central African nations have an effective incidence near or equal to 0 \[[@R01]\].
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RCC is the seventh most common form of neoplasm in the developed world. The surveillance, epidemiology, and end results (SEER) statistics report that in the US, about 74,000 new cases of kidney cancer were diagnosed in 2019, accounting for 4.2% of all cancer diagnoses (almost double the global average). The incidence was first reported in 1975 as 7.1/100,000. In 2016, this resulted in an incidence rate of 14.9/100,000. This steady rise has made kidney cancer one of the fastest-growing cancer diagnoses in the US. However, since peaking at 16.0/100,000 in 2008, kidney cancer incidence has plateaued \[[@R02]\].

Mortality {#s2b}
---------

The GLOBOCAN statistics report mortality of 175,000 people from kidney cancer in 2018. This figure constitutes 1.8% of global cancer deaths. With approximately 114,000 men and 61,000 women perishing from the disease in 2018, the RR of mortality for men is 1.87, even greater than the relative incidence risk (1.71) ([Fig. 2](#F2){ref-type="fig"} \[[@R07]\]). The cumulative risk of death is 0.28% among men worldwide and 0.12% among women, with ASRs of 2.6 and 1.1, respectively \[[@R01]\] ([Fig. 3](#F3){ref-type="fig"} \[[@R07]\]).
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![Bar chart showing estimated age-standardized incidence and mortality rates (World) in 2018, kidney, both sexes, all ages. Data obtained from GLOBOCAN 2018 \[[@R07]\].](wjon-11-079-g003){#F3}

In the US, SEER program estimates that for the year 2020 the number of new cases of kidney cancer is 73,750 and deaths is 14,830, accounting for 2.4% of all cancer-related deaths. Despite a doubling incidence, the age-standardized mortality in 2016 was the same as in 1975 when the statistic was first reported, 3.6/100,000. Mortality peaked at 4.3/100,000 in the years 1992 - 1994, and has since gradually declined to current levels, likely due to improving diagnostic modalities and treatments \[[@R02]\].

Survival {#s2c}
--------

With a 76% 5-year relative survival rate in the US (2009 - 2015), RCC is the deadliest urological cancer. This survival rate has markedly improved since a low of 46.8% in 1977. Survival is highly dependent on the stage at diagnosis, with a 5-year relative survival of 93% for stage I, localized disease, 72.5% for stage II/III regional disease (local lymph node involvement) and only 12% for stage IV metastatic disease \[[@R02], [@R08]\] ([Fig. 4](#F4){ref-type="fig"}). About one-third of cases are diagnosed as metastatic, and a further 20-50% will progress to metastatic cancer despite surgical resection \[[@R9]\]. A large retrospective study of seven Latin American countries and Spain found the 5-year survival for resected RCC to be 86.1%. Age, nodal metastases, performance status (Karnofsky score \< 80), fat invasion, tumor necrosis and tumor size (\> 7 cm) were all significantly associated with worsened survival (in order of descending significance) \[[@R10]\]. Mangone et al have studied the trends in net survival from kidney cancer among six European Latin countries (SUDCAN population-based study) and found that, though there were some differences in survival, there were significant improvements in most countries \[[@R11]\].
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Among those enrolled in clinical trials, a univariable analysis found those in the US/Canada with metastatic RCC had significantly higher survival than those in Western Europe (20.3 vs. 17.4 months), a difference which was not found in the multivariant analysis. Clinical trial participant survival was more variable in Latin America, Asia and Eastern Europe \[[@R12]\].

Etiology and Histology {#s3}
======================

Ninety percent of RCCs are of the clear cell, papillary and chromophobe histological subtypes, with the clear cell being the most common and aggressive. These subtypes have significant prognostic and treatment-predictive value \[[@R13]\]. Clear cell RCC, which accounts for 75% of diagnoses, is a tumor of renal stem cells commonly in the proximal nephron and tubular epithelium and is most likely to hematogenously metastasize to the lungs, liver and bones \[[@R14]\]. Inactivating somatic mutations or deletions in the von Hippel-Lindau (VHL) tumor-suppressor gene region (chromosome arm 3p) are implicated in as many as 45% of clear cell carcinoma cases. Those inheriting germline variants of this gene (VHL disease) and the tuberous sclerosis genes account for 5% of clear cell cases and are at an increased risk of younger-age, bilateral RCC \[[@R15]\]. While papillary RCC, which accounts for 10% of cases, has better survival than the clear cell, the prognosis is highly variable based on post-operative histological staining. Type 1 (basophilic) papillary carcinoma is typically higher-grade and more often associated with ganglial metastases and venous invasion than type 2 (eosinophilic) tumors. Papillary RCC largely resembles renal cortical adenoma in architecture and genetic abnormalities (trisomy 7 and 17 and loss of the Y chromosome); however, renal cortical adenomas tend to be smaller (\< 1.5 cm). Chromophobe RCC represents 5% of cases and carries the best prognosis, as metastases occur in only 7% of cases. Chromophobe RCC appears grossly, histologically and genetically similar to oncocytomas, with both being well-circumscribed, involving deletions of chromosomes Y and 1, arising from collecting duct intercalated cells (involved in acid-base regulation), and associated with Birt-Hogg-Dube syndrome. Chromophobe RCC can be distinguished from oncocytomas with the absence of a central scar and a characteristic perinuclear halo. Medullary RCC is a rare form of RCC typically found in patients with sickle cell trait/disease or beta-thalassemia \[[@R16]\].

Risk Factors {#s4}
============

Unmodifiable {#s4a}
------------

### Age {#s4a1}

Sporadic RCC is a disease of older adults. The average of diagnosis in the US is 64, though most patients are diagnosed between ages 65 and 74 (cumulatively) \[[@R02]\]. Those with VHL disease develop RCC at an average age of 44 and are much more likely to be diagnosed with bilateral disease \[[@R17]\]. The largest increase in incidence in the US over the past decades has been among those 75 and older \[[@R02]\]. Papillary RCC diagnoses were also significantly more likely to be made among those \> 60 than clear cell RCC, while chromophobe RCC diagnosis does not seem to be significantly associated with age, hinting at different mechanisms and timelines of pathogenesis among the histological subtypes \[[@R18]\].

### Sex {#s4a2}

Like most neoplasms, RCC is more common in men, with men accounting for about two-thirds of global cases and deaths \[[@R01]\]. Part of this increased risk may be explained by greater rates of modifiable risk factors such as smoking, hypertension and obesity among men. Men also have lower survival rate \[[@R02]\]. By histological subtype, papillary RCC patients were the least likely to be women, while chromophobe RCC patients were far more commonly women than clear cell or papillary (but still not quite at a 1:1 ratio) \[[@R18]\]. The exact mechanism is not clear, but there is an increased risk of RCC with parity among women and also a possible correlation with hormonal factors \[[@R19]-[@R21]\].

### Race {#s4a3}

In the US, African Americans, Hispanic Americans and Native Americans have a greater risk of RCC than White Americans. One retrospective study found that Hispanic Americans had an almost three-fold increased odds of early RCC diagnosis, while Native Americans had an over six-fold increased odds, an effect that was especially pronounced for clear cell RCC. Interestingly, among Hispanics, speaking Spanish as one's primary language was associating with an increased risk of advanced RCC diagnosis \[[@R22]\]. While African Americans are typically diagnosed at an earlier stage of RCC than whites \[[@R23]\], their survival rates tend to be worse \[[@R24], [@R25]\] ([Fig. 5](#F5){ref-type="fig"} \[[@R08]\]). One study found that among comparable T1 RCC patients, African Americans were more likely to have positive surgical margins following robotic nephrectomy \[[@R26]\]. Interestingly, the clear cell subtype of RCC is more common among Caucasian Americans (partially due to increased risk of VHL disease) while the papillary subtype is more common among those of African or Caribbean descent \[[@R27]\]. Suggested factors underlying the racial disparity in RCC diagnosis and survival among minorities include education and socioeconomic status, diet and physical inactivity, poor living conditions, access to healthcare and loss to follow-up \[[@R25]\].
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Modifiable {#s4b}
----------

### Smoking {#s4b1}

Tobacco smoking is one of few modifiable risk factors for RCC (and largely the most significant), similar to lung cancer and bladder cancer. Cigarette smoke contains many carcinogens such as polycyclic aromatic hydrocarbons and beta-naphthylamine, as well as the highly addictive neurotransmitter-modulating substance nicotine. As they are filtered through the nephron, these particles are metabolized and promote inflammation and induce DNA damage, paving the way for carcinogenesis. One large retrospective analysis found current and former smokers had a 1.5- and 1.6-fold RR of RCC, respectively \[[@R28]\]. Increasing pack-years has been associated with increased risk (up to 2.03 for those with 20+ pack-years), and RR was significantly reduced among those who had quit over 10 years ago \[[@R29]\]. Continued cigarette smoking after RCC diagnosis has also been associated with significantly worsened overall survival (OS) and progression-free survival (PFS) in advanced disease \[[@R30]\].

### Obesity {#s4b2}

Meta-analyses have found a consistent association between increased body mass index (BMI) and risk of RCC, much like with breast cancer, colorectal cancer and many other neoplasms. While the precise pathogenesis remains unelucidated, obesity promotes resistance to insulin and insulin-like growth factor (facilitating uncontrolled tumor growth) \[[@R31]\], releases inflammatory cytokines, and disrupts metabolic homeostasis (such as stimulating the release of adiponectin) \[[@R32]\], leading to the over-production of DNA damaging free radicals. A study of the European Prospective Investigation into Cancer and Nutrition (EPIC) found that high BMI was associated with a 2.25 RR of RCC \[[@R33]\]. Another study found that obesity was particularly associated with an increased risk of the clear cell (RR = 1.8) and chromophobe (RR = 2.2) subtypes of RCC, while papillary RCC did not seem to show an association (RR = 1.2) \[[@R34]\]. One study found that adding roughly 5 kg in body weight could increase RCC risk by 25% in men and 35% in women \[[@R35]\]. According to a meta-analysis, regular physical activity was shown to reduce RCC risk by 22% \[[@R36]\].

### Diet and alcohol {#s4b3}

Diets rich in cruciferous have been associated in some studies with a lower risk of RCC \[[@R37]\], while those heavy in meat-based protein and fat and dairy are associated with higher risk \[[@R38]\]. However, these associations were disputed by the EPIC study in Europe, which did not find any significant association between diet and RCC risk \[[@R39]\]. The correlation between diet and RCC seems to be not as strong as in other neoplasms like gastric and colorectal cancer. While moderate drinking seems to show a slight protective effect against RCC, heavy drinking is associated with increased risk among both men and women \[[@R40], [@R41]\].

### Hypertension {#s4b4}

Hypertension damages the renal glomerulus and tubular apparatus and has been associated with an increased risk of kidney cancer. A case-control study in the US found that hypertension doubled overall risk (OR) for RCC. White Americans with hypertension had an ORR of 1.9, while the OR was 2.8 for African Americans (possibly due to an increased prevalence of obesity). Time since hypertension diagnosis and poorly controlled hypertension both significantly further increased the risk of developing RCC. Both hypertension and obesity have been implicated in the racial disparity of RCC incidence and mortality in the US \[[@R42]\]. The aforementioned EPIC study found that among Europeans, high systolic (\> 160 mm Hg) and diastolic (\> 100 mm Hg) blood pressures were associated with a 2.48 and 2.34 RR of RCC, respectively \[[@R43]\]. The use of statins to control blood pressure among those with RCC could significantly improve survival; however, statin use was not shown to prevent RCC diagnosis \[[@R44]\].

### Occupational exposure and drugs {#s4b5}

While RCC is not classified as an occupational neoplasm (like bladder cancer or mesothelioma), several occupational exposures have been noted. Most prevalently, trichloroethylene, a solvent used in degreasing agents, spray fixatives for art, and public drinking water has been associated with RCC, liver cancer and lymphoma \[[@R45]\]. Specifically, the chemical seems to be activated by the pathway involved in glutathione transfer in the liver and kidney, causing DNA adducts, renal cell genotoxicity and cytotoxicity \[[@R46]\]. An estimated 10% of the US population has detectable levels of the toxic agent in their blood \[[@R45]\]. Other occupational chemicals associated with RCC include asbestos, benzene, vinyl chloride, herbicides and cadmium, as well as an overdose of the popular painkiller acetaminophen (US trade name Tylenol). Regular use of non-aspirin non-steroidal anti-inflammatory drugs has also been associated with an increased risk of RCC, likely because these agents inhibit prostaglandins which are necessary for proper kidney function \[[@R47]\].

Prevention and Screening {#s5}
========================

Smoking cessation, a healthy diet and regular exercise are the most evidence-backed means of prevention for RCC. The Mediterranean diet and United States Department of Agriculture (USDA) designed Dietary Approaches to Stop Hypertension (DASH) diet, both of which consist of high levels of fruits, vegetables and plant products and low levels of red meat and fatty dairy, have been shown to decrease the risk of many cancers and have favorable effects on body weight, hypertension, glucose and lipids, all of which are implicated in RCC tumorigenesis \[[@R48]\]. Better control of hypertension through lifestyle modification, statins and other interventions is associated with a lower risk of RCC \[[@R41], [@R42]\]. Early interventions could be of particular benefit to minority populations in the US like African Americans and Hispanics, whose higher rates of early-age hypertension may predispose them to worse RCC outcomes \[[@R42]\]. Regular exercise helps to maintain healthy blood pressure and weight, but may also further reduce the risk of cancer independent of the aforementioned factors \[[@R49]\]. Smoking cessation gradually decreases the risk of RCC, with an over a two-fold reduction in risk after 10 years of cessation \[[@R30]\].

Greater awareness of RCC risk factors and access to healthcare, especially among underserved populations in the developed world and developing nations, may help reduce disparities and improve outcomes. Populations at heightened risk of RCC due to genetic predispositions, high blood pressure, obesity or smoking and drinking status should be followed regularly and offered imaging (with ultrasound, MRI, or CT scan) when suspected as the prognosis is far more favorable when diagnosed early \[[@R25]\]. There are no randomized controlled trials (RCTs) to advocate for screening imaging studies in suspected RCC patients. Public health campaigns against smoking and obesity have likewise played a role in curbing the growing incidence of RCC in the developed world and could serve as examples for developing nations faced with an increasing disease burden.

Conclusion {#s6}
==========

While RCC accounts for 2% of global cancer diagnoses and deaths, it has rapidly grown in incidence in the developed world, becoming the ninth most common cancer diagnosis in the US. RCC is the deadliest urological neoplasm and has a dismal late-stage, 5-year survival rate of 12%. Clear cell is the most common histological subtype, followed by papillary and chromophobe, and shows the strongest associations with many modifiable and unmodifiable risk factors. RCC is more common in older men and minorities in the US, where significant racial disparities persist in RCC survival. Modifiable risk factors such as smoking, obesity, uncontrolled hypertension, poor diet and occupational exposure are prime candidates for prevention efforts in the campaign against this aggressive cancer.
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